Alpha-Synuclein Epitope Segmentation for Lewy Body Clearance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, characterized by Lewy bodies and alpha-synuclein aggregation, lack effective therapeutic options to prevent or ameliorate neuropathology and cognitive impairment.
Innovation Solution
Administration of synuclein fragments, antigens that mimic synuclein, or antibodies to specific epitopes of synuclein or beta-amyloid to induce an immunogenic response, reducing the number of inclusions in transgenic mice and potentially treating Parkinson's disease and other Lewy body-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immunogenic agents (synuclein fragments, antigens, or antibodies) are administered to induce an immune response against alpha-synuclein aggregates, then the number of Lewy bodies and alpha-synuclein inclusions is reduced, but the complexity of the treatment regimen increases
Solution Approach 1:
The patent segments the alpha-synuclein protein into specific epitopic fragments (e.g., amino acid residues 70-140, particularly 124-140) to use as immunogenic agents. This segmentation allows the immune system to target specific regions of the pathogenic protein, improving treatment effectiveness while using smaller, more manageable antigen structures rather than the entire protein
Solution Approach 2:
The patent uses antibodies (such as 8A5, 6H7, and other monoclonal antibodies) as intermediary agents that mediate the immune response against alpha-synuclein aggregates. These antibodies serve as intermediaries between the administered immunogenic agents and the pathogenic aggregates, facilitating the reduction of Lewy bodies through immune-mediated clearance mechanisms
2Reliability
If multiple immunogenic agents are administered to target different epitopes of synuclein, then the immunogenic response is enhanced, but the manufacturing and administration complexity increases
Solution Approach 1:
The patent combines multiple immunogenic agents targeting different epitopes of alpha-synuclein into a single therapeutic regimen. For example, it combines antibodies 8A5 (targeting residues 70-140) and 6H7 (targeting residues 1-20) to elicit a broader and stronger immune response against various regions of the alpha-synuclein protein, thereby enhancing treatment effectiveness through merged therapeutic actions
3Reliability
If the patent develops a new immunogenic treatment for Parkinson's disease, then effective therapy is provided, but the time and resources required for development and clinical validation increase
Solution Approach 1:
The patent employs preliminary validation of immunogenic agents in transgenic mouse models that overexpress human alpha-synuclein and develop Lewy body pathology before advancing to human clinical trials. This preliminary action in animal models provides proof-of-concept data and reduces the risk of failure in later clinical stages, thereby optimizing the overall development timeline and resource allocation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively induces an immunogenic response that reduces alpha-synuclein and beta-amyloid aggregates, offering a promising therapeutic regime for preventing or treating diseases associated with Lewy bodies and improving motor and cognitive symptoms.
Implementation Method 1
Administration of synuclein fragments, antigens that mimic synuclein, or antibodies to specific epitopes of synuclein or beta-amyloid to induce an immunogenic response
Data Source
AI summary
The invention provides improved agents and methods for treatment of diseases associated with synucleinopathic diseases, including Lewy bodies of alpha-synuclein in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the Lewy body. The methods are particularly useful for prophylactic and therapeutic treatment of Parkinson's disease.